Brokerages expect that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will post earnings of ($1.34) per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Adamas Pharmaceuticals’ earnings. The highest EPS estimate is ($1.21) and the lowest is ($1.47). Adamas Pharmaceuticals posted earnings per share of ($1.04) during the same quarter last year, which would suggest a negative year over year growth rate of 28.8%. The business is expected to announce its next earnings results after the market closes on Thursday, November 1st.
According to Zacks, analysts expect that Adamas Pharmaceuticals will report full year earnings of ($5.37) per share for the current fiscal year, with EPS estimates ranging from ($5.61) to ($4.95). For the next year, analysts forecast that the company will post earnings of ($3.77) per share, with EPS estimates ranging from ($4.17) to ($3.08). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) EPS for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.12. Adamas Pharmaceuticals had a negative return on equity of 104.86% and a negative net margin of 1,138.59%.
A number of research firms have recently weighed in on ADMS. Leerink Swann reaffirmed an “outperform” rating on shares of Adamas Pharmaceuticals in a research note on Friday, October 19th. HC Wainwright set a $45.00 price objective on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 6th. ValuEngine lowered Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 28th. BidaskClub lowered Adamas Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 1st. Finally, Zacks Investment Research lowered Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, October 8th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. Adamas Pharmaceuticals presently has an average rating of “Buy” and an average price target of $44.78.
In other news, CFO Alfred G. Merriweather sold 1,665 shares of the company’s stock in a transaction dated Friday, September 21st. The stock was sold at an average price of $19.18, for a total value of $31,934.70. Following the completion of the transaction, the chief financial officer now owns 25,460 shares of the company’s stock, valued at $488,322.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 24.60% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. FNY Investment Advisers LLC bought a new position in Adamas Pharmaceuticals during the second quarter valued at approximately $130,000. Metropolitan Life Insurance Co. NY boosted its stake in Adamas Pharmaceuticals by 43.2% during the second quarter. Metropolitan Life Insurance Co. NY now owns 7,606 shares of the specialty pharmaceutical company’s stock valued at $196,000 after buying an additional 2,293 shares during the last quarter. Sei Investments Co. boosted its stake in Adamas Pharmaceuticals by 49.8% during the first quarter. Sei Investments Co. now owns 7,627 shares of the specialty pharmaceutical company’s stock valued at $182,000 after buying an additional 2,536 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new position in Adamas Pharmaceuticals during the second quarter valued at approximately $203,000. Finally, GSA Capital Partners LLP bought a new position in Adamas Pharmaceuticals during the second quarter valued at approximately $212,000. 95.23% of the stock is owned by institutional investors.
NASDAQ ADMS opened at $16.97 on Tuesday. The stock has a market capitalization of $430.15 million, a PE ratio of -4.27 and a beta of 1.39. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.92 and a quick ratio of 9.74. Adamas Pharmaceuticals has a twelve month low of $15.03 and a twelve month high of $44.00.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
See Also: Outstanding Shares, Buying and Selling Stocks
Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.